Get the Stockscreener App
1.85
3.65%
-0.07
After Hours:
1.85
Milestone Pharmaceuticals Inc stock is traded at $1.85, with a volume of 863.81K.
It is down -3.65% in the last 24 hours and down -12.32% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.92
Open:
$1.95
24h Volume:
863.81K
Relative Volume:
0.74
Market Cap:
$157.24M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.3309
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
-3.14%
1M Performance:
-12.32%
6M Performance:
+41.22%
1Y Performance:
+28.47%
1-Day Range:
$1.85
$1.9574
1-Week Range:
$1.76
$1.9574
52-Week Range:
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.85 | 163.19M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-11-25 | Initiated | Wells Fargo | Overweight |
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Can Milestone Pharmaceuticals Inc. stock resist sector downturnsEarnings Performance Report & Verified Short-Term Plans - newser.com
How Milestone Pharmaceuticals Inc. stock reacts to oil prices2025 Performance Recap & Step-by-Step Swing Trade Plans - newser.com
Advanced analytics toolkit walkthrough for Milestone Pharmaceuticals Inc.Quarterly Risk Review & Smart Money Movement Alerts - newser.com
Milestone Pharmaceuticals (MIST) Highlights Promising Results fo - GuruFocus
Using Bollinger Bands to evaluate Milestone Pharmaceuticals Inc.Take Profit & Risk Adjusted Buy and Sell Alerts - newser.com
How to forecast Milestone Pharmaceuticals Inc. trends using time seriesJuly 2025 Selloffs & Free Real-Time Volume Trigger Notifications - newser.com
Milestone Pharmaceuticals Reports Positive Efficacy and Safety Data for Etripamil Nasal Spray in Management of Paroxysmal Supraventricular Tachycardia - Quiver Quantitative
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025 - Stock Titan
Combining price and volume data for Milestone Pharmaceuticals Inc.Inflation Watch & Weekly Stock Performance Updates - newser.com
Will Milestone Pharmaceuticals Inc. stock remain a Wall Street favoriteRate Cut & Fast Gain Swing Trade Alerts - newser.com
What Fibonacci levels say about Milestone Pharmaceuticals Inc. reboundTrade Exit Summary & Verified Entry Point Signals - newser.com
Is Milestone Pharmaceuticals Inc. stock bottoming outMarket Risk Summary & Community Consensus Picks - newser.com
Can Milestone Pharmaceuticals Inc. recover in the next quarterEarnings Recap Summary & Community Supported Trade Ideas - newser.com
How Milestone Pharmaceuticals Inc. stock performs during Fed tightening cyclesEarnings Growth Summary & Growth-Oriented Investment Plans - newser.com
Real time social sentiment graph for Milestone Pharmaceuticals Inc.Portfolio Performance Summary & Weekly Market Pulse Alerts - newser.com
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright - MSN
How to interpret RSI for Milestone Pharmaceuticals Inc. stock2025 Macro Impact & Technical Confirmation Alerts - newser.com
What momentum shifts mean for Milestone Pharmaceuticals Inc.Weekly Trade Analysis & Reliable Entry Point Alerts - newser.com
What the charts say about Milestone Pharmaceuticals Inc. today2025 Biggest Moves & Low Risk High Win Rate Picks - newser.com
Is it too late to sell Milestone Pharmaceuticals Inc.July 2025 Analyst Calls & Real-Time Volume Spike Alerts - newser.com
Can Milestone Pharmaceuticals Inc. stock maintain operating marginsPortfolio Value Summary & Daily Stock Trend Watchlist - newser.com
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Average Rating of "Hold" by Brokerages - MarketBeat
Detecting support and resistance levels for Milestone Pharmaceuticals Inc.Oil Prices & Fast Exit/Entry Strategy Plans - newser.com
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):